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Background/aim: Monitoring of lung function alone does not adequately identify the high-risk
patients among elderly asthma and COPD cohorts. The additional value of Health-Related
Quality of Life (HRQoL) development in the detection of patients with a disabling disease in
clinical practice is unclear. The aim of this study was to statistically examine the individual
development of HRQoL measured using respiratory-specific AQ20 and generic 15D question-
naires.
Materials and methods: The HRQoL of COPD (N Z 739) and asthma (N Z 1329) patients was
evaluated at 0, 1, 2, and 4 years after recruitment. To determine a five-year HRQoL change
for each patient we used mixed-effects modelling for linear trend.
Results: In COPD, the majority (60e80%) of the individuals showed declining trend, whereas in
asthma, the majority (46e71%) showed no attenuation in HRQoL. The proportion of constant
decliners was estimated higher with the 15D both in asthma (6.3%) and COPD (6.3%) than with
AQ20 (3.5 and 4.5%, respectively). The first measurement of HRQoL was found to predict future
development of HRQoL. In asthma, obesity-related diseases such as hypertension, diabetes
and gastro-esophageal reflux disease best explained the decline, whereas in COPD, age and
the level of bronchial obstruction were the main determinants.
Conclusion: Based on the five-year follow-up, the HRQoL trends significantly diverging from
each other could be identified both among the asthma and COPD patients. Compared toearch Unit for Pulmonary Diseases and Division of Pulmonology, Helsinki University Central Hospital,
inland. Tel.: þ358 503747924.
sinki.fi (J. Koskela).
3 Elsevier Ltd. All rights reserved.
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464 J. Koskela et al.cross-sectional HRQoL, the HRQoL trend over a clinically relevant period of time allows us to
ignore, to a great extent, the random error of self-assessed HRQoL and thus, it may offer a
more accurate measure to describe the disease process.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Several cross-sectional studies comparing the clinical find-
ings and Health-Related Quality of Life (HRQoL) in asthma
and chronic obstructive pulmonary disease (COPD) have
lately been published [1e5]. In COPD, HRQoL has been
shown to correlate with lung function, exercise capacity,
exacerbations, dyspnoea and comorbidities, but all the
correlations found are rather weak when linked to clinical
manifestations [6]. In asthma, severity of the disease,
comorbidities such as chronic rhinosinusitis and allergic
rhinitis have been found to be associated with impaired
HRQoL [7,8]. Different clinical determinants might be
identified with different types of instruments e.g. due to
better sensitivity of disease-specific instruments.
HRQoL instruments have proven valuable in clinical in-
terventions and as the primary or secondary endpoint in
efficacy studies [9e13]. In clinical practice when chronic
diseases are managed, the value of HRQoL remains how-
ever, unclear. Potentially HRQoL can provide important
information on patients’ perception of disease burden.
Both asthma and COPD are complex diseases. We have used
to consider COPD as a progressive disease leading to dis-
abilities through severe dyspnoea and disease exacerba-
tions, while in asthma the lung functions are stored and
long-term prognosis is generally good. In the elderly pa-
tient populations the features of asthma and COPD are
often overlapping [14]. Monitoring of lung functions alone
does not necessarily dissect these patients having either
progressive or non-progressive disease [15,16]. As the
treatments in obstructive lung diseases have evolved
rapidly, there is a need for better diagnostics. The assess-
ment of longitudinal HRQoL together with other clinical
measures might improve the identification of the high-risk
patients.
Several HRQoL questionnaires have been evaluated and
compared in chronic obstructive airway diseases, both
generic and airway-specific [17e32]. None of them has
shown to be superior to others [33]. The questionnaires are
usually designed to assess the patients’ present HRQoL,
which is a highly subjective measure and by definition leads
to some degree of random error in the analysis and thus
demands caution when interpreting of the results. Howev-
er, if several repeated measurements are available over a
clinically relevant period of time and the within-patient
variation is acceptable in relation to the number of cross-
sectional measurements, the error could be greatly
ignored. Consistency of multiple consecutive measure-
ments and thus the potential predictive value of the first
measurement are poorly understood at the moment.
The aim of this study was to examine the individual
development of HRQoL among elderly asthma and COPD
patients. Patients’ clinical status was assessed at baselineand HRQoL followed by prospective measurements at cross-
sectional time points 0, 1, 2, and 4 years. Our main
objective was to study whether it was possible to identify
patients with constantly poor development of HRQoL. We
also studied the predictive value of a first HRQoL mea-
surement and finally determined the risk factors for poor
development of HRQoL.
Materials and methods
Subjects
The patients with asthma, smoking-related COPD or chronic
bronchitis were recruited from Turku and Helsinki Univer-
sity Hospitals in Finland. We invited all adult patients with
ICD10 J44 and J45 codes who had visited the hospitals in the
years 1995e2006 [34,35]. A total of 2068 patients (27% of all
invited) contacted the research staff by phone and visited
the research clinic. The comprehensive retrospective
medical records covered at least 5 years prior to the
enrolment. Based on clinical and diagnostic data, the main
component of their obstructive disease was defined as
smoking-related COPD or chronic bronchitis in 739 and as
asthma in 1329 patients (Finnish Chronic Airway Disease
(FinnCAD) cohort) [35].
Clinical characteristics
From the medical records, we identified the results of the
latest flow-volume spirometry including bronchodilatation
test, weight, and height and smoking status of the patient.
The reference value for FEV1 (forced expiratory volume in
1 s) was used [36]. All the given diagnoses stated in the
medical records were carefully evaluated, especially time
of the onset and certainty of the diagnosis. Common co-
existing diseases were classified at the time of recruiting
based on a diagnosis often made by a specialist of the field.
Deaths were tracked from the population registry.
The Ethics Committee of the Hospital District of Helsinki
and Uusimaa has approved the study.
HRQoL
Patients’ HRQoL was assessed at 0, 1, 2 and, 4 years using
both the generic 15D and Airway-specific Questionnaire 20
(AQ20) [25,37]. The AQ20 questionnaire is a modification of
the St. George’s Respiratory Questionnaire (SGRQ) consist-
ing of 20 ‘yes’/‘no’/‘does not concern me’ questions. The
AQ20 has discriminative properties and responsiveness
comparable to more complex questionnaires such as the
SGRQ and CRQ [26]. The summary score is obtained by
summing up the ‘yes’ eanswers. The summary score is
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and 20 indicating multiple symptoms of airway-specific
health.
The 15D questionnaire consists of 15 dimensions
(mobility, vision, hearing, breathing, sleeping, eating,
speech, excretion, usual activities, mental function,
discomfort and symptoms, depression, distress, vitality,
and sexual activity) of health status, each having 5 levels on
an ordinal scale. The scaled score is given on a 0e1 scale,
where 0 Z being dead, 1 Z full HRQoL. The 15D ques-
tionnaire has been shown to be reliable, valid and sensitive
for many different chronic diseases [27,37,38] including
asthma and COPD and comparable to EQ-5D, SF-6D, and
HUI3 [20,23,27,37,39]. A change of 0.03 in the 15D score is
considered to be the Minimum Clinically Important Differ-
ence (MCID) in the sense that people can on average feel
the difference [40].
The change in the total scores for each participant over
time is expressed as HRQoL trends separately for both in-
struments. The trend was computed only for those who had
3 measurements within the five-year follow-up period.
Due to the scoring systems the trends show in opposite
directions.Analysis
In order to incorporate the variation between patients’
self-reported measurements of HRQoL, we used a mixed-
effects model. The development of HRQoL in the five-year
period for each patient was modelled as linear in time since
the entry into the study.
Intraclass correlations were used to determine the
amount of resemblance between sequential measurements
for each patient. Zero correlation indicates that the past
measurement of a particular patient yields no information
about the future scores and one indicates that the mea-
surements of a patient are perfectly correlated.
To identify the uncertainty related to individual trends
we used a Markov Chain Monte Carlo (MCMC)-sampler. The
algorithm was used to produce 10,000 possible trends of
development for each patient (the posterior distribution
of trends) based on the actual data. When more than 8500
out of 10,000 samples were negative, a patient was
considered to be a constant decliner (85% probability
level). Highest Posterior Density intervals were deter-
mined to describe the variation of development at popu-
lation level parameters.
The value of the baseline HRQoL score in predicting
future development of patients HRQoL was evaluated using
Receiver Operating Characteristic (ROC). The constantly
declining development was explained with the baseline
HRQoL measurement in a binary logistic regression model,
in which the entire study population of each cohort was
included. Area Under Curve (AUC) was then derived to
describe the diagnostic value of a first measurement of
HRQoL.
To further analyse the risk factors of poor development
of HRQoL, we performed Bayesian Models Averaging (BMA).
Scaled posterior effect probability varies from 0 to 100,
indicating the relevance of a variable in describing the poor
development of QoL. In contrast to p-value, low values ofeffect probabilities are also informative suggesting no as-
sociation between endpoint and a variable. We only show
the risk factors with a posterior effect probability of >20%,
using each instrument in both asthma and COPD. Factors
with posterior effect probabilities lower than 20% were
considered not to be associated with poor development of
HRQoL [41].
All analysis was done using R Statistical Software version
2.15.Results
Patient populations
The HRQoL of COPD (N Z 739) and asthma (N Z 1329)
patients was evaluated by a generic (15D) and airway-
specific (AQ20) HRQoL instrument at cross-sectional time
points 0, 1, 2, and 4 years. The patients were clinically
profiled at baseline based on retrospective clinical data.
All participants having 3 measurements of HRQoL and
relevant clinical data available were included in the
analysis (Table 1). Compared to the COPD patients, the
asthma patients were younger (mean 58 vs. 68 years,
p < 0.001), showed female majority (mean 74 vs. 33%,
p < 0.001), and had suffered the disease longer (mean 14
vs. 8 years, p < 0.001). COPD patients had more pack
years (mean 42 vs. 7 years, p < 0.001), poorer lung
functions (mean FEV1 59 vs. 89% of expected, p < 0.001),
and more frequently co-existing chronic diseases such as
cardiovascular disease (28 vs. 7%, p < 0.001), diabetes (16
vs. 6%, p < 0.001), and alcohol abuse (15 vs. 3%, p < 0.001)
than the asthma patients. At any given time point, the
mean HRQoL level was constantly lower in the COPD
cohort compared to that of the asthma cohort by both
instruments (Table 1).Five-year-trends in COPD showed significantly
poorer development than those in asthma
The variation of HRQoL measurements within a patient was
evaluated using the intraclass correlations for both patient
groups and for both instruments. The correlations were
acceptable and equal for each subgroup: for asthma in
AQ20 0.80 and in 15D 0.82; and for COPD 0.81 and 0.81,
respectively.
In COPD, the majority (60.1e80.1%) of the individuals
showed declining HRQoL. The overall mean decline in the
15D score was 0.005/year (95% CI 0.007 to 0.002), and
in the AQ20 score 0.092/year (95% CI 0.02 to 0.19) (Fig. 1).
In asthma, the majority (45.9e70.5% % of the patients) of
the trends suggested no decline. For the 15D the overall
mean change in the score was 0.002/year (95% CI 0.003
to 105) and in AQ20 the mean trend was slightly improving
0.10/year (95% CI 0.17 to 0.05).
The proportion of patients with declining trends was
higher both in asthma (539/54.1%) and COPD (443/80.1%)
when 15D was used. With AQ20 the proportion of decliners
was 308/29.5% in asthma and 357/60.1% in COPD,
respectively.
Table 1 Clinical characteristic of the asthma and COPD patients studied with two separate HRQoL instruments.
Asthma COPD
15D (N Z 996)
N (%)
AQ 20 (N Z 1045)
N (%)
15D (N Z 548)
N (%)
AQ 20 (N Z 594)
N (%)
Age, yrsa 58.3, (57.5, 59.1) 59.9, (35.6, 84.2) 68.1, (55.0, 81.1) 68.3, (55.1, 81.5)
Maleb 256, (25.7) 265, (25.3) 347, (62.7) 371, (62.5)
FEV1% predicted
a 88.9, (87.8, 89.9) 88.6, (87.5, 89.6) 58.6, (56.9, 60.2) 58.6, (57.0, 60.1)
Pack yearsa 7.2, (6.5, 8.0) 7.3, (6.5, 8.0) 42.0, (41.2, 42.8) 42.4, (41.0, 44.0)
Body mass indexa 27.3, (27.0, 27.6) 27.4, (27.1, 27.8) 26.8, (26.4, 27.3) 27.0, (26.5, 27.4)
Coronary diseaseb 52, (5.2) 51, (4.8) 111, (20.3) 119, (20.0)
Cerebrovascular diseaseb 22, (2.2) 23, (2.2) 40, (7.3) 42, (7.1)
Peripheral arterial occlusive diseaseb NA NA 32, (5.8) 37, (6.2)
Hypertensionb 313, (31.4) 338, (32.3) 227, (41.4) 249, (41.9)
Alcohol abuseb 32, (3.2) 34, (3.3) 81, (14.8) 89, (15.0)
Hypothyreosisb 79, (7.9) 103, (10.3) 42, (7.7) 45, (7.6)
Cancerb 83, (8.3) 98, (9.8) 49, (8.9) 51, (8.6)
Gastro-esophageal refluxb 257, (25.8) 274, (27.5) 139, (25.4) 148, (25.0)
Arrhythmiab 114, (11.4) 124, (11.9) 99, (18.1) 116, (19.5)
Chronic sinusitisb 168, (16.9) 177, (17.8) NA NA
Diabetesb 50, (5.2) 62, (5.9) 87, (15.9) 93, (15.7)
Psychiatric conditionsb
Yes, mild depression/
anxiety meds needed occasionally
Yes, moderate, meds needed regularly
Yes, psychotic conditions, meds and/or
hospital admissions needed regularly
45, (4.5)
65, (6.5)
145, (14.6)
38, (3.8)
49, (4.7)
70, (6.7)
155, (14.8)
45, (4.3)
15, (2.7)
34, (6.2)
87, (15.9)
40, (7.3)
17, (2.9)
36, (6.1)
90, (15.2)
39, (6.6)
Duration of disease, yearsa 14.4, (13.7, 15.2) 14.6, (13.8, 15.3) 8.2, (7.8, 8.5) 8.3, (7.9, 8.6)
Mean HRQoL score at:
Baselinea 0.865, (0.859, 0.871) 7.20, (6.91, 7.48) 0.799, (0.793, 0.811) 8.05, (7.66, 8.45)
1 Follow-upa 0.868, (0.861, 0.874) 6.84, (6.54, 7.13) 0.792, (0.785, 0.804) 8.15, (7.74, 8.57)
2 Follow-upa 0.864, (0.858, 0.871) 6.70, (6.41, 6.98) 0.788, (0.782, 0.801) 8.20, (7.79, 8.62)
4 Follow-upa 0.862, (0.855, 0.870) 6.67, (6.36, 6.97) 0.783, (0.773, 0.794) 8.13, (7.68, 8.58)
NA Z not available.
a Mean (95% CI).
b Number (%).
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declining HRQoL
The accuracy of identifying patients with constantly
declining trends was dependent on the within-patient
variation between the sequential HRQoL measurements
and the number of measurements available for each pa-
tient. Markov Chain Monte Carlo sampling showed that only
a fraction of decliners presented in Fig. 1 showed
constantly poor development of HRQoL. The majority of the
constant decliners were identified based on four measure-
ments (95-71%). The proportion of constant decliners was
higher for 15D both in asthma (6.3%) and COPD (6.3%) than
with AQ20 (3.5 and 4.5%, respectively) (Fig. 2). The vast
majority of the patients were thus considered non-
decliners (the patients who showed either non-significant
decline or improving trends).
To evaluate the clinical significance of the difference in
trajectories found between the constant decliners and
rest of the patients, we used the MCID value determined
for 15D. Among constant decliners, MCID occurred in 2.2
years (95% CI 1.9e2.5 years) in asthma, whereas among
the non-decliners, it took 75 years (42.9e300 years,p < 0.0001). In COPD the difference was not that extreme,
but still clinically meaningful and significant 1.7 (1.5e2.0
years) vs. 6.8 years (6.1e7.7 years, p Z 0.0007). The
decline rates for AQ20 were significantly accelerated in
constant decliners both in asthma (p < 0.0001) and in
COPD (p < 0.0001).
A large majority of constant decliners were identified
based on four measurements of HRQoL (15D Asthma 83%,
COPD 77% and AQ20 Asthma 95%, COPD 96%).
Baseline HRQoL score had predictive value
Since the poor individual baseline HRQoL showed corre-
lation with the declining individual HRQoL trend (Fig. 2),
we studied the value of the baseline HRQoL score in pre-
dicting the future change of HRQoL using the area under
ROC curve (AUC) statistic. We estimated the proportion of
patients who would be correctly classified as constant
decliners based on the baseline HRQoL measurement only
(Fig. 3), when the entire study population of each cohort
was included in the analysis. Models showed good accu-
racy: AUC in asthma was 0.84 when 15D and 0.80 when
AQ20 was used. In COPD, the AUCs were 0.83 and 0.78,
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constant decliners in asthma were 0.84 (Odds Ratio for
constant decline Z 5.6, 95% CI 3.31e9.59) for 15D and
>9.5 (OR Z 3.7, 95% CI 1.5e9.2) for AQ20. For COPD the
cut-off points were <0.77 (OR Z 11.7, 95% CI 4.8e28.6)
and >9.5 (OR Z 4.8, 95% CI 1.2e20.1), respectively.
Distinct profiles of risk factors accelerate the poor
development of HRQoL in asthma and COPD.
All clinical variables (Table 1) characterizing the pa-
tient at baseline were included in the BMA analysis. The
risk factors accelerating the poor development
exceeding statistical significance for each subgroup and
instrument are shown in Table 2. The risk factors of poor
development were mostly parallel regardless of the in-
strument (15D or AQ20), but the profile was remarkably
different in asthma and COPD. In asthma, obesity-related
diseases such as hypertension, diabetes, and GERD were
the most important risk factors of poor development of
HRQoL. In COPD, age and the level of bronchial
obstruction were the main determinants. The effect of
the most severe psychiatric conditions was seen in both
asthma and COPD.Figure 1 Posterior distribution of regression coefficients (ZHRQ
COPD patients. For both questionnaires, 0 trend means no change b
grey and improving trends in white, note the opposite scales.Discussion
The present longitudinal study among elderly COPD and
asthma patients combined both prospective and retro-
spective study elements. HRQoL was followed in a pro-
spective manner while the patients’ clinical profile was
based on retrospective medical records at baseline. The
results showed that both the airway-specific AQ20 and
generic 15D show trends in HRQoL, and identified constant
decliners both among COPD and elderly asthma patients
over a period of 5 years.
As expected, the mean development of HRQoL was
significantly weaker in COPD than in asthma, and this dif-
ference was found both by the generic and the respiratory-
specific instrument. In COPD, the declining trend was
observed in 60e80% of the patients, while in asthma,
HRQoL was sustained or even improved, and the declining
trend was observed only in 30e54% of the patients. At the
posterior probability level of >85%, 6.3% of the patients in
both disease groups were identified as constant decliners
by the generic HRQoL instrument, and 3.5e4.5% using the
airway-specific instrument. In the identification of theoL trends) for the 15D and AQ20 trends among the asthma and
ased on the 5 year follow-up, the declining trends are shown in
Figure 2 15D and AQ20 trends in relation to the baseline HRQoL level among the asthma and COPD patients, note the opposite
scales. Black dots represent the individuals who were defined as patients with constantly declining trends.
468 J. Koskela et al.constant decliners, among both asthma and COPD patients,
the baseline HRQoL score was shown to have a strong pre-
dictive value. In asthma, obesity-related diseases such as
hypertension, diabetes, and GERD explained the poor
development, while in COPD, the level of bronchial
obstruction was the main determinant.
Traditionally, in the study of HRQoL, the mean score of a
study population is computed at one cross-sectional point
of time, or the mean scores before and after an interven-
tion are compared. These approaches ignore an essential
proportion of uncertainty, since the differences in each
patient’s individual development are discarded. In the
present study design, multiple consecutive measurements
of HRQoL allowed us to evaluate individual development
over time and to further analyse the clinical variables
explaining the differences between the patients. Consid-
ering the nature of asthma and COPD, a five-year follow-up
time is long enough to bring out significant variationbetween patients. In this study, we concentrated especially
on the patients who showed declining trend and assessed
them individually in contrast to methods traditionally used
in clinical studies.
The limitations of the study were related to the retro-
spective study design and the number of HRQoL measure-
ments performed per patient. Some clinical variables such
as 6 Minute Walk Test and certain lung function measure-
ments determining the nature of the disease were not
available for majority of the patients and thus, those were
excluded from the study. Individual differences in medi-
cation were not incorporated into the mixed-effects model
either, which might have some effects on outcomes. In
Finland asthma and COPD are treated according to national
guidelines that follow the international recommendations
[42,43]. In asthma, inhaled corticosteroids form a strong
basis for the treatment, while in COPD, the medication is
still mostly directed to symptom relief.
Figure 3 ROC curves and AUC statistics of the baseline HRQoL measurements in prediction of the constant decliners within the
next five years.
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on the number of patients studied in each sub-cohort, the
number of the HRQoL measurements available for each
particular patient, and the within-patient variation be-
tween the measurements. Statistical power of the analysis
improved clearly when the number of measurements
increased from three to four: for 15D 77e83% of the con-
stant decliners were found among patients with four mea-
surements. For AQ20 the corresponding proportions were
even higher, 95%e96%. Thus the probability to identify
constant decliners would improve substantially with one
more measurement for each patient. The results are also
dependent on the probability level at which the results are
examined. The higher probability level, the more stringent
threshold for the dissection of each patient into a risk or a
non-risk patient (in this case a constant decliner or non-
decliner). In this study, we used the probability level of
85%, which represented a rather conservative threshold,
and thus the number of reported decliners is also rathercautious. Due to the progressive nature of COPD, one would
have expected to find more constant decliners in COPD than
in asthma. The difference between the disease groups was
most likely equalized due to discontinuation of the study in
the COPD group due to deaths (N Z 60) and very severe
disease (N Z 26) before the 3-4 cross-sectional HRQoL
measurements were gathered.
To demonstrate the difference among the constant de-
cliners compared to that in the rest of the patients, we used
MCID available for 15D. A change in HRQoL equal to the MCID
accumulated among constant decliners in approximately two
years in both COPD and in asthma. Among COPD non-
decliners it took 7 years, and in asthma 75 years.
When the value of a first HRQoL measurement in pre-
dicting whether the patient will be a constant decliner
during the next five years was estimated, the test showed
robustness in both disease groups (AUC for 15D 0.78e0.84)
as future decliners were successfully identified. The pa-
tient’s baseline HRQoL level and HRQoL trend for the next
Table 2 Clinical risk factors that accelerated the individual decline of HRQoL determined among the asthma and COPD pa-
tients by two separate HRQoL instruments.
Clinical variable Constant decliners in asthma Constant decliners in COPD
15D (N Z 63) AQ20 (N Z 37) 15D (N Z 35) AQ20 (N Z 26)
Posterior
effect
probabilitya
Effect Posterior
effect
probability
Effect Posterior
effect
probability
Effect Posterior
effect
probability
Effect
Age (þ1 year) 64.9 0.0004
BMI (þ1 unit) 100.0 0.0008
Hypertension 77.0 0.0055 22.9 0.050
Diabetes 60.6 0.115
Gastro oesophageal
reflux disease
51.4 0.0038
Severe psychiatric
conditions
22.5 0.105 31.2 0.0042
FEV1 % of predicted
40e64 24.1 0.0022
<40 31.5 0.0070 73.9 0.007 65.5 0.365
a Posterior effect probabilities (PEP) and posterior means of the effects (5-year effect) for risk factors with PEP exceeding 20%.
470 J. Koskela et al.five years were significantly correlated in constant de-
cliners. Baseline 15D < 0.8 and AQ20 score >9.5 predicted
both in asthma and COPD constantly declining trend during
the forthcoming 5 years.
Several earlier reports have shown that cross-sectional
HRQoL is only weakly or not at all correlated with FEV1
among COPD patients [18,21,26]. These results are in line
with the results found in the present cohort. FEV1 affected
HRQoL only in the late stages of the disease (Kilpela¨inen
et al. unpublished data). Therefore, it was to some extent
surprising that FEV1, in addition to age, was the strongest
risk factor for the HRQoL trend in COPD.
The method presented here is to our knowledge a novel
approach in HRQoL analyses and so far rarely used in clinical
medicine in general. The results suggest that the HRQoL
trend over timemay serve as amore robust outcome than the
HRQoL level at a certain cross-sectional time point. In addi-
tion themethod allows labelling a patient as a high or low risk
patient at certain probability level. This qualitymay become
beneficial whenmore personalised health care is developed.
In asthma, obesity-related comorbidities were the most
important risk factors of the poor development of HRQoL.
The comparison between generic and airway-specific in-
struments suggested that more decliners could be found
using a generic instrument, most likely due to its ability to
detect changes also in co-existing diseases.Appendix A. Supplementary data
Supplementary data related to this article can be found
online at http://dx.doi.org/10.1016/j.rmed.2013.12.001.
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